comparemela.com
  1. Home
  2. Live Updates
  3. Egfr Mutant Non Small Cell Lung Cancer - Breaking News

Latest Breaking News On - Egfr mutant non small cell lung cancer - Page 1 : comparemela.com

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

United statesJaime schneiderHarvard medical schoolThoracic cancersMassachusetts general hospitalEgfr mutant non small cell lung cancer

Furmonertinib Plus Icotinib Elicits Antitumor Activity in EGFR+ NSCLC With CNS Metastases

First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.

Hualin chenHospital of guangdong medical universityEuropean lung cancer congressLung cancerPulmonary oncologyAffiliated hospitalGuangdong medical universityLung cancer congressEgfr mutant non small cell lung cancerCentral nervous system cns metastasesPhase 2 trial chictr2200060151

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.